Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Should Do More To Boost Transparency To Industry, Firms Say

This article was originally published in The Gray Sheet

Executive Summary

FDA's plans to improve transparency with industry do not go far enough, device and biotech firms say in recent comments to the agency.

You may also be interested in...



FDA Device Center Analyzes Why It Missed PMA Review Goals

FDA pre-market approval reviews tend to take longer when the medical officer leaves the review team, when clinical trial data issues arise and when companies engage in "excessive" back and forth with FDA during the review process, according to a recent FDA analysis.

FDA Unveils Plan To Boost Transparency To Industry

Included in a new list of things FDA will do to improve its communications with manufacturers is a vow to respond more quickly to industry questions.

Coty Continues Licensing Spree With Etro; CEO Nabi Shares Prestige Fragrance Vision

At CAGNY 2024, CEO Sue Nabi discussed Coty’s prestige fragrance strategy, including growing emphasis on ultra-premium offerings and continued focus on fashion-driven licenses, the same day the company announced a long-term fragrance licensing deal with Italian brand Etro.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel